Heron Therapeutics Inc vs D Wave Quantum Inc — how do they compare? Heron Therapeutics Inc trades at $0.33 (market cap $64.59M), while D Wave Quantum Inc trades at $20.94 (market cap $7.72B). The key difference: D Wave Quantum Inc is far larger — about 119.5× Heron Therapeutics Inc's market cap, and D Wave Quantum Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | QBTS | |
|---|---|---|
Market Cap | $64.59M | $7.72B |
Sector | Health | Technology |
52-Week High | $1.49 | $44.78 |
52-Week Low | $0.32 | $12.98 |
Enterprise Value | $171.33M | $7.23B |
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.3409, up 3.24% today, but faces bearish technical signals with 18 sell indicators versus 6 buys. The company reported Q2 2026 revenue of $37.7 million but missed earnings expectations with a $0.03 per share loss. Despite strong analyst support (94.7% buy ratings), fundamental challenges persist with negative net income margins and elevated EV/EBITDA of 34.03.
Investment outlook remains cautious due to consistent earnings misses and negative cash flow from operations. The primary opportunity lies in analyst optimism and potential product growth, while risks include ongoing profitability challenges and competitive pressures in the biotechnology sector.
D-Wave Quantum (QBTS) trades at $20.75, up 2.77% today, but faces bearish technical signals amid mixed earnings performance. The company reported a Q2 2026 loss of $0.10 per share, missing estimates, while revenue remained flat at $3.1 million. Despite negative profitability metrics, analyst consensus remains unanimously bullish with a $38.29 price target, reflecting optimism about quantum computing adoption and strong bookings growth.
The stock presents high-risk speculative potential with significant valuation concerns trading at 584x sales. While institutional interest and government funding support long-term quantum computing prospects, persistent losses and declining revenue create substantial execution risk. Investors must weigh Wall Street optimism against fundamental weaknesses in this emerging technology play.
Trailing returns across standard periods
Latest headlines on both assets
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →